Vaxcyte, Inc. — Director's Dealing 2022

Dec 30, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2022-12-28

Reporting Person: Dhaliwal Harpreet S. (SVP Cml Mfg & Supply Chain)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-12-28	Common Stock	M	3990	$25.06	Acquired	21808	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-12-28	Stock Option (Right to Buy)	$25.06	D	3990	Acquired	2031-11-07	Common Stock (3990)	Direct

Footnotes

F1: Includes 928 shares acquired under the Vaxcyte, Inc. Employee Stock Purchase Plan on November 17, 2022.

F2: 1/48 of shares subject to the option vest on January 30, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.